MDXG
MiMedx Group, Inc. Healthcare - Biotechnology Investor Relations →
MiMedx Group, Inc. (MDXG) closed at $4.12 as of 2026-03-20, trading 33.5% below its 200-week moving average of $6.19. This places MDXG in the extreme value zone. The stock is currently moving closer to the line, down from -29.3% last week. With a 14-week RSI of 3, MDXG is in oversold territory.
A big spike in selling this week — 2.2x the usual volume, and the price dropped. Sometimes this kind of heavy selling marks the end of a decline. The idea is that the last reluctant holders have finally sold, leaving fewer sellers left to push the price lower.
Over the past 896 weeks of data, MDXG has crossed below its 200-week moving average 15 times. On average, these episodes lasted 30 weeks. Historically, investors who bought MDXG at the start of these episodes saw an average one-year return of +11.6%.
With a market cap of $612 million, MDXG is a small-cap stock. The company generates a free cash flow yield of 10.3%, which is notably high. Return on equity stands at 21.6%, indicating strong profitability. The stock trades at 2.4x book value.
Share count has increased 30.2% over three years, indicating dilution. MDXG passes our Buffett quality screen: high return on equity, low debt, and positive free cash flow. This stock also meets the Yartseva multibagger criteria as a small-cap with strong free cash flow yield and reasonable book value.
Over the past 17.2 years, a hypothetical investment of $100 in MDXG would have grown to $229, compared to $1071 for the S&P 500. MDXG has returned 4.9% annualized vs 14.7% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 1 open-market purchase totaling $1,268,000. Notably, these purchases occurred while MDXG is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been volatile over the past several years, making the quality of earnings harder to assess.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: MDXG vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MDXG Crosses Below the Line?
Across 15 historical episodes, buying MDXG when it crossed below its 200-week moving average produced an average return of +11.7% after 12 months (median +2.0%), compared to +13.7% for the S&P 500 over the same periods. 50% of those episodes were profitable after one year. After 24 months, the average return was -14.1% vs +29.6% for the index.
Each line shows $100 invested at the moment MDXG crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MDXG has crossed below its 200-week MA 15 times with an average 1-year return of +11.6% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jan 2009 | Jun 2012 | 176 | 90.3% | -58.8% | +64.8% |
| May 2016 | May 2016 | 3 | 5.5% | +98.7% | -41.9% |
| Aug 2016 | Sep 2016 | 3 | 3.6% | +126.3% | -43.6% |
| Jan 2017 | Feb 2017 | 1 | 3.1% | +107.1% | -47.1% |
| Feb 2017 | Feb 2017 | 1 | 1.4% | -1.8% | -48.3% |
| Feb 2018 | Dec 2020 | 147 | 87.7% | -59.8% | -47.4% |
| Sep 2021 | Oct 2021 | 4 | 12.1% | -47.0% | -33.0% |
| Dec 2021 | Jun 2023 | 77 | 54.8% | -54.0% | -31.8% |
| Oct 2023 | Nov 2023 | 4 | 5.2% | -4.3% | -32.2% |
| Apr 2024 | Apr 2024 | 3 | 5.1% | +6.2% | -36.0% |
| Jul 2024 | Aug 2024 | 3 | 6.4% | +10.8% | -36.2% |
| Sep 2024 | Oct 2024 | 8 | 14.6% | +16.1% | -33.0% |
| Apr 2025 | May 2025 | 1 | 0.7% | N/A | -34.8% |
| Jun 2025 | Jun 2025 | 3 | 5.9% | N/A | -31.8% |
| Jan 2026 | Ongoing | 11+ | 33.5% | Ongoing | -32.5% |
| Average | 30 | — | +11.6% | — |
Frequently Asked Questions
Is MDXG below its 200-week moving average?
Yes. As of 2026-03-20, MiMedx Group, Inc. (MDXG) is trading 33.5% below its 200-week moving average of $6.19. The current price is $4.12.
What is MDXG's 200-week moving average price?
MiMedx Group, Inc.'s 200-week moving average is $6.19 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when MDXG drops below its 200-week moving average?
MDXG has crossed below its 200-week moving average 15 times in our data. On average, buying at that moment produced a one-year return of +11.6%. These dips have historically been decent entry points. These episodes lasted 30 weeks on average.
Is MDXG a good value right now?
Here's what our data says about MDXG as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 3 (oversold). Free cash flow yield is 10.3%. Return on equity is 21.6%. Price-to-book is 2.4x. This is not a buy or sell recommendation — always do your own research.
How does MDXG compare to the S&P 500?
Over the past 17.2 years, $100 invested in MDXG would have grown to $229, compared to $1071 for the S&P 500. That's 4.9% annualized vs 14.7% for the index. MDXG has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20